Skip to main content
Premium Trial:

Request an Annual Quote

Clarification: Dec 20, 2004


Due to an editing oversight, a quote from Mark Stolorow, executive director of Orchid Cellmark, was truncated in last week’s issue of BioInform. The full quote is as follows: “We have adequate quality assurance controls in place to help us identify and correct any foreseeable quality assurance contingency. If I knew that it weren’t, I would correct it, so we operate under the assumption that we have adequate controls in place, and in the 16 year history of our company here at our Germantown site, that has been the case.”

Filed under

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.